Add to my selection

REKAMBYS (rilpivirine)

Medicine - Posted on Oct 21 2025

Active substance (DCI)

rilpivirine

history (3)

10/8/25

REKAMBYS (rilpivirine) - HIV-1 infection only in adolescents at least 12 years of age and weighing at least 35 kg

Summary of opinion Favourable opinion for reimbursement in the indication extension, in combination with cabotegravir, for t...

CAV :
54321

icône flèche
2/1/23

REKAMBYS (rilpivirine) - HIV

Reassessment and MA amendments. Key points Favourable opinion for maintenance of reimbursement for the treatment of human im...

CAV :
54321

icône flèche
4/21/21

REKAMBYS (rilpivirine)

Key points Favourable opinion for reimbursement for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, ...

CAV :
54321

icône flèche

Technical information

ATC code

J05AG05

Manufacturer

VIIV HEALTHCARE

Presentation

REKAMBYS 900 mg, suspension injectable à libération prolongée
1 flacon(s) en verre de 3 ml avec seringue(s) avec adaptateur(s) pour flacon avec aiguille(s) (CIP : 34009 302 198 7 4)

All our publications

Drug therapy

Immunologic deficiency syndromes

Paediatrics

Sexually transmitted diseases

Virus diseases

My account

You do not have a saved search

REKAMBYS (rilpivirine)

REKAMBYS (rilpivirine) - HIV-1 infection only in adolescents at least 12 years of age and weighing at least 35 kg

REKAMBYS (rilpivirine) - HIV

REKAMBYS (rilpivirine)

Follow us :